Natco Pharma Ltd Q3 FY2025 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/48fvagay2mp9lgnir7wzzdux.pdf

Key Takeaways


The Revlimid Cycle: Where We Are

Rajeev Nannapaneni: "I think that's the elephant in the room, I think you have to accept that earnings will drop in March'27. How much will it drop? I think that's the question I am directly indicating."

GLP-1 Opportunity: Semaglutide


Pipeline: What Matters Beyond Revlimid


Base Business & Non-Revlimid Growth


Capital Allocation: Cash, Acquisitions & Debt

Rajeev Nannapaneni: "But what I can strive to do is that we try to build a business which is more stable at a base level by doing an acquisition, which we have not been able to execute, obviously. I will be very honest about it. That's probably one thing you probably didn't get right."

Guidance & Commitments

CommitmentSpecificsTimeline
FY25 PAT₹1,800–2,000 cr; management still hopeful to meet thisFY25 end
Revlimid allocationOne-third of total market volume begins sellingQ4 FY25 (March launch)
FY26 earningsMaintain same earnings as FY25, subject to Revlimid price erosionFY26
March '27 earnings dropMore than 50–60% decline when Revlimid contribution fallsMarch '27
Semaglutide India launchInjectable GLP-1 launch, subject to regulatory approvalMarch 2026
Crop science break-evenReach ₹120–150 cr revenue to come closer to break-evenNext year (FY26)
AcquisitionsTwo targets: one for ROW business, one for U.S. front endNo timeline given

Key Metrics

MetricQ3 FY25
Consolidated total revenue₹651.1 cr, vs ₹795.6 cr in Q3 FY24
Consolidated net profit₹132.4 cr, vs ₹212.7 cr in Q3 FY24
Other income₹76 cr, includes a one-time pre-tax gain of ₹90 cr from sale of land
Cash and liquid investments₹3,264 cr as of December 31, 2024
Debt₹241 cr as of December 31, 2024
Net cash~₹3,000 cr as of December 31, 2024
R&D expenditure7% to 8% of net sales typically, 8% to 10% of revenue
FY25 PAT expectation₹1,800 to ₹2,000 cr, management hopeful of meeting this guidance
Revlimid allocationOne-third of total market volume, starting March 2025
Crop Health Sciences revenue₹15–₹16 cr per quarter, targeting ₹130–₹140 cr next year to approach breakeven
Subsidiary sales (Q3)₹109 cr, year-to-date subsidiary sales at ₹408 cr
Ex-Revlimid quarterly revenue₹475 cr in Q3 FY25
FY27 earnings outlookDrop of more than 50% to 60% expected post-Revlimid